What's Going On With AbbVie Stock Friday?
AbbVie shares are edging higher Friday following Thursday's positive Phase 3 trial results for its menstrual migraine drug, atogepant.
AbbVie's migraine medicine passed an important test, which is why people are buying the stock today. When a company's new medicine works well in testing, watch to see if it helps their business grow and makes money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.